Optimal use of lipid-altering therapy: guidelines versus evidence

Abstract

“an important question is whether adding an additional lipid-altering drug to a statin that specifically modifies HDL cholesterol or triglycerides will further reduce adverse clinical events.”

Key Words:

• atherosclerosis
• cardiovascular mortality
• coronary heart disease
• dyslipidemia
• hyperlipidemia
• lipid-lowering drugs